Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025Endocrine ConnectionsOpen Access

Long-term Efficacy of dapagliflozin combined with bifidobacterium triple viable tablets on metabolic syndrome and gut microbiota in overweight/obese patients with type 2 diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

KLKunyi LiZLZhi LiLLLifeng Liu

Discussion

Loading...

Member takes

Overview

Randomized controlled trial shows improvements in HbA1c and gut microbiota in overweight/obese T2D patients, suggesting added benefits of probiotics.

Key Points

  • Dapagliflozin combined with probiotics significantly reduced HbA1c by 1.8% and weight by 5.2 kg compared to control.
  • Participants receiving the combination therapy experienced notable improvements in LDL-C and HDL-C levels, with all results being statistically significant.
  • This randomized controlled trial involved 120 overweight/obese type 2 diabetes patients over a 24-week period, highlighting its comprehensive design.
  • Combining dapagliflozin with probiotics may optimize treatment outcomes in metabolic syndrome, promoting better management of type 2 diabetes.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68af35e3cf1dd9ea359ea03chttps://doi.org/10.1530/ec-25-0219
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of SGLT2 Inhibitors + DPP‐4 Inhibitors on Urine Microbiota in Type 2 Diabetes2026 · 1 citations
  2. 2Study of the clinical effect of dapagliflozin on metabolic indices in type 2 diabetic patients with different obesity phenotypes2025
  3. 3Effects of Dapagliflozin on Obese Patients With Type 2 Diabetes: A Prospective Observational Study From Bangladesh2025
  4. 4Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes2025 · 3 citations
  5. 5Improvement of Cardiometabolic Control with Dapagliflozin in Patients with Type 2 Diabetes in Primary Care: The AGORA-AP Study2025